	US 12,227,511 B2
	Bicyclic compounds as kinase modulators, methods and uses thereof
Vikrant Arun Adsool, Singapore (SG)
Assigned to Agency for Science, Technology and Research, Singapore (SG)
Filed by Agency for Science, Technology and Research, Singapore (SG)
Filed on May 8, 2023, as Appl. No. 18/144,641.
Application 18/144,641 is a continuation of application No. 17/265,175, granted, now 11,702,425, previously published as PCT/SG2019/050355, filed on Jul. 23, 2019.
Claims priority of application No. 10201806566V (SG), filed on Aug. 1, 2018.
Prior Publication US 2023/0391789 A1, Dec. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 491/08 (2006.01); C07D 215/233 (2006.01); C07D 401/12 (2006.01); C07D 451/06 (2006.01); C07D 451/14 (2006.01)

CPC C07D 491/08 (2013.01) [C07D 215/233 (2013.01); C07D 401/12 (2013.01); C07D 451/06 (2013.01); C07D 451/14 (2013.01)]

20 Claims

1. A method for treating cancer in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate or prodrug thereof:

wherein

R₁and R₂are independently selected from optionally substituted alkyl, optionally substituted alkenyl, and optionally substituted alkynyl;

X is selected from optionally substituted cycloalkylene, optionally substituted heterocyclylene, optionally substituted arylene, and optionally substituted heteroarylene;

Y is optionally substituted cycloalkylene; and

Z is selected from optionally substituted —N-heterocyclyl, optionally substituted —NH(heterocyclyl), optionally substituted —NH(cycloalkyl), optionally substituted —NH(aryl), and optionally substituted —NH(heteroaryl);

wherein at least one of X, Y or Z is an optionally substituted bridged moiety;

wherein the cancer is selected from thyroid cancer, kidney cancer, colorectal cancer, gastrointestinal cancer, skin cancer, lung cancer, and bladder cancer.